Skip to content

PTHS PTHS UNC License Agreement U.S.Patents — Number of patents

Similar metrics at other companies

Intellicheck, Inc. logo
IDNUnited States — Number of patents
10
NuScale Power logo
SMRNumber of patents
30.0%
InterDigital logo
IDCCPatents, net
$319.16M+0.7%
Intellicheck, Inc. logo
IDNCanada — Number of patents
1
Nasdaq, Inc. logo
NDAQIndex — Number of types of license agreements (in agreements)
0.50.0%
ADMA Biologics logo
ADMANumber Of FDA Approved Product
30.0%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept pths:NumberOfPatentsObtained.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's unc license agreement u.s.patents — number of patents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's UNC license agreement u.s.patents — number of patents?
PTHS (PTHS) reported UNC license agreement u.s.patents — number of patents of 12 in Q1 2026.
What does UNC license agreement u.s.patents — number of patents mean?
This metric represents the total count of active U.S. patents held or licensed by the company specifically related to the UNC license agreement portfolio. It serves as a key indicator of the intellectual property strength and the legal exclusivity protecting the company's clinical-stage therapeutic candidates. A higher number of patents typically reflects a more robust competitive moat and greater potential for long-term commercialization of proprietary pain management technologies.